<DOC>
	<DOCNO>NCT03005015</DOCNO>
	<brief_summary>The primary objective multicenter , randomize phase II trial ass efficacy , measure progression-free survival ( PFS ) , lenvatinib compare doxorubicin advance recurrent endometrial cancer . The main secondary objective evaluate predictive value Ang-2 lenvatinib activity establish cutoff value potential selection criterion phase III . Other secondary objective assess tolerability safety lenvatinib set overall survival , response disease control .</brief_summary>
	<brief_title>Lenvatinib Second Line Endometrial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Female subject age ≥18 year time inform consent World Health Organization ( WHO ) Performance Status 0 1 Patients histologically confirm endometrial cancer include serouspapillary clear cell histology . Uterine carcinosarcoma allow . Radiographic evidence disease progression accord RECIST 1.1 1 prior systemic , platinumbased chemotherapy regimen metastatic primary unresectable endometrial carcinoma surgical radiotherapy treatment option exist . Patients disease progression follow platinumbased chemotherapy administer either adjuvant neoadjuvant treatment also eligible . Patients may receive prior radiotherapy / adjuvant chemotherapy early highrisk disease Patients may receive prior treatment anthracyclines Blood sample available retrospective central assessment Ang2 level Patients may prior therapy provide follow condition meet : Surgery radiation therapy : washout period 14 day subject must recover adequately toxicity and/or complication radiotherapy major surgery prior start therapy . Systemic antitumor therapy investigational agent : washout period 21 day ( 5 x halflife ) Recovery toxic effect prior therapy ≤ Grade 1 per National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE v4 . ) except alopecia Adequate contraceptive measure Signed write informed consent Inadequate hematologic , renal hepatic function Abnormal cardiac function</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>